- Home
- DSY vs TLSA Comparison
DSY vs TLSA Comparison
Compare DSY & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- TLSA
- Stock Information
- Founded
- DSY 2020
- TLSA 2013
- Country
- DSY China
- TLSA United Kingdom
- Employees
- DSY N/A
- TLSA N/A
- Industry
- DSY
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- TLSA Health Care
- Exchange
- DSY Nasdaq
- TLSA Nasdaq
- Market Cap
- DSY 73.6M
- TLSA 87.8M
- IPO Year
- DSY N/A
- TLSA 2000
- Fundamental
- Price
- DSY $1.04
- TLSA $1.08
- Analyst Decision
- DSY
- TLSA
- Analyst Count
- DSY 0
- TLSA 0
- Target Price
- DSY N/A
- TLSA N/A
- AVG Volume (30 Days)
- DSY 204.5K
- TLSA 1.0M
- Earning Date
- DSY 02-10-2025
- TLSA 05-09-2025
- Dividend Yield
- DSY N/A
- TLSA N/A
- EPS Growth
- DSY 120.37
- TLSA N/A
- EPS
- DSY 0.01
- TLSA N/A
- Revenue
- DSY $7,323,356.00
- TLSA N/A
- Revenue This Year
- DSY N/A
- TLSA N/A
- Revenue Next Year
- DSY N/A
- TLSA N/A
- P/E Ratio
- DSY $89.28
- TLSA N/A
- Revenue Growth
- DSY 16.37
- TLSA N/A
- 52 Week Low
- DSY $0.75
- TLSA $0.41
- 52 Week High
- DSY $13.47
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- DSY 35.26
- TLSA 44.39
- Support Level
- DSY $0.98
- TLSA $0.96
- Resistance Level
- DSY $1.19
- TLSA $1.30
- Average True Range (ATR)
- DSY 0.16
- TLSA 0.17
- MACD
- DSY 0.01
- TLSA -0.06
- Stochastic Oscillator
- DSY 17.92
- TLSA 17.65
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.